RespireRx Pharmaceuticals Inc (RSPI)

[haysaw]

Sooner or later, the principal of the firm, Matt Garza, is probably going to end up being the target of a civil or criminal prosecution.

That's not saying much, considering the diversity and sheer number of lawyers -- and victimized, naïve, miserable and shady people -- out there.

In this case, I'm wondering if "Dusty" Garza got paid to produce that report (see below). It reads like a semi-formal advert. What does "Single Pharmaceutical-Based Strategy" even mean? Is it a Hi/Low Impact combo drug? Will they call it the 'Compact,' or 'Highlow Compactor?'

I noticed that there didn't seem to be any trading activity (accumulating or selling) following this scripted PR. Either it isn't a good sign for his subscription/trader base, or it's just too early. The last Q&A profile by Garza was on AMPE (Ampio Pharmaceuticals, on Sep 14th, 2011), and the stock went from the high 8's to just over 9 (briefly), back down to 6 on increased volume, and is now ~ $7.5/sh (however, several other investment services were trading/following it also). Garza might have gotten a little too excited with his timing (unless he was front-running/P&D'ing--duh!), but at least he was at the right place for help--maybe :)

Clarification on the speculation above - The following is the disclosure at the bottom of the article and on the website:

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com